Staidson Beijing Biopharma (300204.SZ) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · China · ISIN CNE100001237

Price
17.18 CNY
Market cap
9.30 bn CNY
P/E (2025)
–
P/S (2025)
42.23
Dividend yield
0.00 %
Net margin
-35.31 %
Return on equity (ROE)
-9.47 %
Return on assets (ROA)
-6.14 %

Staidson Beijing Biopharma financials

Fiscal year20242025
Revenue324.82 m CNY220.23 m CNY
Gross profit262.55 m CNY170.15 m CNY
Operating income-33.61 m CNY-78.41 m CNY
EBIT-33.60 m CNY-79.83 m CNY
Net income-144.84 m CNY-77.76 m CNY
Diluted EPS – continuing operations-0.30 CNY-0.16 CNY

Full history since 2007, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Staidson Beijing Biopharma

Staidson (Beijing) BioPharmaceuticals Co., Ltd. primarily engages in the research, development, production, and marketing of therapeutic and biological drugs in China. The company offers protein drugs, including therapeutic monoclonal antibody drugs; chemical drugs; and drugs for urinary, intestinal, infectious, autoimmune, nervous system, and other diseases. It also provides treatments for respiratory and critical care illnesses, and neurological disorders. Its product portfolio includes Mouse Nerve Growth factor for injection, Compound Polyethylene Glycol Electrolyte Powder (IV), Aspirin enteric-coated tablets, Compound polyethylene glycol (3350) electrolyte oral solution, Compound polyethylene glycol (3350) electrolyte vitamin C powder. Staidson (Beijing) BioPharmaceuticals Co., Ltd. was founded in 2002 and is based in Beijing, China.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.